Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.
Fournier E, Inchiappa L, Delattre C, Pignon JM, Danicourt F, Bemba M, Roche-Lestienne C, Daudignon A, Decool G, Roumier C, Dumezy F, Fournier L, Grardel N, Preudhomme C, Duployez N. Fournier E, et al. Among authors: dumezy f. Leuk Lymphoma. 2019 Jul;60(7):1827-1830. doi: 10.1080/10428194.2018.1562185. Epub 2019 Jan 7. Leuk Lymphoma. 2019. PMID: 30616415 Review. No abstract available.
Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.
Gazeau N, Derrieux C, Nibourel O, Berthon C, Grardel N, Goursaud L, Boyer T, Dumezy F, Coiteux V, Quesnel B, Preudhomme C, Roche-Lestienne C, Duployez N. Gazeau N, et al. Among authors: dumezy f. Leukemia. 2020 Aug;34(8):2230-2233. doi: 10.1038/s41375-020-0715-2. Epub 2020 Jan 27. Leukemia. 2020. PMID: 31988437 No abstract available.
Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.
Guénot C, Lacombe F, Allou K, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Maynadié M, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC; Groupe d’Etude Immunologique des Leucémies (GEIL). Guénot C, et al. Among authors: dumezy f. Leukemia. 2019 Jul;33(7):1814-1816. doi: 10.1038/s41375-019-0393-0. Epub 2019 Feb 5. Leukemia. 2019. PMID: 30723257 No abstract available.
CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.
Lefèvre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Grardel N, Poulain S, Staumont-Sallé D, Seneschal J, Salles G, Ghomari K, Terriou L, Leclech C, Morati-Hafsaoui C, Morschhauser F, Lambotte O, Ackerman F, Trauet J, Geffroy S, Dumezy F, Capron M, Roche-Lestienne C, Taieb A, Hatron PY, Dubucquoi S, Hachulla E, Prin L, Labalette M, Launay D, Preudhomme C, Kahn JE; French Eosinophil Network. Lefèvre G, et al. Among authors: dumezy f. Haematologica. 2015 Aug;100(8):1086-95. doi: 10.3324/haematol.2014.118042. Epub 2015 Feb 14. Haematologica. 2015. PMID: 25682606 Free PMC article.
B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.
Fournier B, Balducci E, Duployez N, Clappier E, Cuccuini W, Arfeuille C, Caye-Eude A, Delabesse E, Bottollier-Lemallaz Colomb E, Nebral K, Chrétien ML, Derrieux C, Cabannes-Hamy A, Dumezy F, Etancelin P, Fenneteau O, Frayfer J, Gourmel A, Loosveld M, Michel G, Nadal N, Penther D, Tigaud I, Fournier E, Reismüller B, Attarbaschi A, Lafage-Pochitaloff M, Baruchel A. Fournier B, et al. Among authors: dumezy f. Front Oncol. 2019 Dec 10;9:1374. doi: 10.3389/fonc.2019.01374. eCollection 2019. Front Oncol. 2019. PMID: 31921638 Free PMC article.
Acute myeloid leukemia with translocation t(3;5): new molecular insights.
Dumézy F, Renneville A, Mayeur-Rousse C, Nibourel O, Labis E, Preudhomme C. Dumézy F, et al. Haematologica. 2013 Apr;98(4):e52-4. doi: 10.3324/haematol.2012.082149. Epub 2013 Feb 12. Haematologica. 2013. PMID: 23403313 Free PMC article. No abstract available.
The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J. Olombel G, et al. Among authors: dumezy f. Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. Blood. 2016. PMID: 26929274 Free article. Clinical Trial. No abstract available.
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Jouault H, Lepelley P, Maynadié M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC; Groupe d'Etude Immunologique des Leucémies (GEIL). Lacombe F, et al. Among authors: dumezy f. Hematol Oncol. 2018 Apr;36(2):422-428. doi: 10.1002/hon.2488. Epub 2017 Dec 7. Hematol Oncol. 2018. PMID: 29218734
16 results